Adbry (tralokinumab-ldrm) is a prescription medication used to treat moderate to severe forms of atopic dermatitis, also called eczema. Adbry is a monoclonal antibody that targets and inhibits the action of Interleukin-13 (IL-13), a protein that plays a crucial role in the development of allergic and inflammatory responses.

Uses:
Adbry is used to treat atopic dermatitis in adults. It is not recommended for use in children under the age of 18.

How to Use:
Adbry is administered as a subcutaneous injection under the skin. It is typically given every two weeks, and the injection site should be rotated to avoid skin irritation. After proper training, patients may be able to self-administer Adbry injections at home.

Dosage:
The recommended dose of Adbry is 150 mg, administered every two weeks. Your healthcare provider will determine the appropriate dosage for you based on your individual needs and medical history.

Mechanism of Action:
Adbry targets Interleukin-13 (IL-13), which is a key mediator in the development of allergic and inflammatory responses in the skin. By binding to IL-13, Adbry inhibits its action and helps suppress inflammation and itchiness associated with atopic dermatitis.

Storage Conditions:
Adbry should be stored in a refrigerator between 2°C to 8°C (36°F to 46°F). It should not be frozen or shaken. Adbry should be protected from light and kept in its original packaging until ready to use.

Precautions:
Before using Adbry, inform your healthcare provider if you have a history of hypersensitivity or allergic reactions to any medications or components of Adbry. It is important to monitor for signs of an allergic reaction, such as rash, hives, swelling, or difficulty breathing.

Interactions:
There are no known drug interactions with Adbry. However, it is important to inform your healthcare provider of any medications, supplements, or herbal products you are currently taking to avoid any potential interactions or adverse effects.

Contraindications:
Adbry is contraindicated in patients with a known hypersensitivity or allergy to tralokinumab or any of its components. Adbry is not recommended for use in children under the age of 18.

Side Effects:
Some common side effects of Adbry include injection site reactions, such as redness, swelling, or pain. Other potential side effects include headache, back pain, nausea, and upper respiratory tract infections. If you experience any unusual or severe side effects, contact your healthcare provider immediately.

Overdose:
There is limited information available on the effects of an overdose of Adbry. If you suspect an overdose has occurred, seek medical attention immediately. Symptoms of an overdose of Adbry may include an increased risk of infections or other serious side effects.

In summary, Adbry is a prescription medication used to treat moderate to severe atopic dermatitis in adults. It is administered as a subcutaneous injection every two weeks, and the dosage is determined by the patient’s individual needs. Adbry targets the Interleukin-13 protein and inhibits its action, which helps suppress inflammation and itchiness associated with atopic dermatitis. While Adbry is generally safe, it may cause some side effects and requires appropriate precautions and storage conditions. Patients should inform their healthcare provider of any medical conditions or medications before using Adbry to avoid any potential interactions or contraindications.